Amylyx Pharmaceuticals Inc

Stock futures edged lower on Tuesday as investors weighed a fresh surge in crude oil prices driven by stalled diplomatic talks and lingering concerns over a prolonged blockade of the Strait of Hormuz. Amylyx Pharmaceuticals climbed 44% after its Phase 3 LUCIDITY trial of avexitide met its primary and all secondary endpoints, with the once-daily injectable reducing Level 2 and Level 3 hypoglycemic events by 55% versus placebo over 16 weeks. Duos Technologies Group rose 21% after reporting upbeat Q2 results and reaffirming its 2026 targets of 25 MW deployed and more than $50M in revenue, while Flexsteel Industries gained 11% after beating FQ4 earnings and revenue estimates and providing above-consensus Q1 sales guidance. Klarna fell 21% after issuing weaker-than-expected Q3 and full-year guidance, citing lower German volumes, FX headwinds, and changes to fair financing accounting, while Fabrinet dropped 18% despite a strong FQ4 beat and above-consensus Q1 guidance. Kulicke & Soffa slid 10% after naming Raj Talluri as President and CEO, and Baidu fell 9% after Q2 revenue and adjusted EPS missed estimates, with online marketing revenue declining 19% and total revenue falling 4% year-over-year to RMB31.3B.

Several biotech stocks reached 52-week highs on August 7, 2026, driven by strong quarterly results and clinical progress. Halozyme Therapeutics surged 20% to $103.30 after reporting second-quarter revenue of $481 million, a 48% year-over-year increase, and estimating full-year 2026 revenues of $1.83 billion to $1.91 billion, representing 31% to 37% growth. Fennec Pharmaceuticals rose over 6% to $11.66 following a 71% jump in first-quarter net sales to $15.1 million from its PEDMARK therapy, with second-quarter results due August 11. Avalyn Pharma climbed over 3% to $34.15 after its April IPO raised about $316 million, while advancing inhaled therapies AP01 and AP02 in Phase 2 trials. Amylyx Pharmaceuticals hit $24.60 as it progresses the Phase 3 LUCIDITY trial for Avexitide and completed enrollment in a Phase 1 ALS study. Chemed Corporation reached $552.72 after revising its full-year revenue growth estimate to 8.25% to 9.25%, with a Medicare cap billing limitation of $7,000, and reporting an 8.8% second-quarter revenue increase to $673 million.

Five biotech stocks featured on RTTNews have delivered substantial gains, with upcoming catalysts that could drive further upside. uniQure N.V. surged 186% since August 2025, driven by positive data for its Huntington's disease gene therapy AMT-130, and is on track to submit regulatory filings in the third quarter of 2026. CareDx Inc. gained 138% since June 2025 after a series of strong earnings reports, raised guidance, and the acquisition of Naveris, with the commercial launch of the NavDx liquid biopsy test as a key catalyst. Adaptive Biotechnologies Corp. rose 130% since May 2025, supported by growing adoption of its clonoSEQ MRD test and multiple guidance raises, with the planned separation of its Immune Medicine business as a potential catalyst. Enliven Therapeutics Inc. jumped 207% since November 2025 on positive Phase 1 data for its chronic myeloid leukemia drug ELVN-001, and expects to initiate a Phase 3 trial in the second half of 2026. Amylyx Pharmaceuticals Inc. climbed 217% since June 2025, with a pivotal Phase 3 data readout for its post-bariatric hypoglycemia drug Avexitide anticipated in the third quarter of 2026.

Guggenheim raised its price target on Amylyx Pharmaceuticals to $40 from $30 and named the stock a Best Idea ahead of Phase 3 LUCIDITY trial results for avexitide in post-bariatric hypoglycemia, expected in the third quarter. The firm expressed confidence the pivotal study will produce favorable outcomes, supporting avexitide's commercial prospects in the estimated $6 billion-plus U.S. market. Separately, Amylyx presented Phase 1 LUMINA trial data for AMX0114 at the European Network to Cure ALS Meeting 2026, showing no drug-related serious adverse events in Cohort 1 and supporting continued dose escalation.